

## Case Series

# Clinical Management of Children and Adolescents with Neurofibromatosis Type 1 Like Phenotypes and Complex Behavioural Manifestations: A Multidisciplinary and Dimensional Approach

Ana Moscoso <sup>1,2</sup>, Aurélie Julien,<sup>2</sup> Antoine Tanet,<sup>2</sup> Angèle Consoli,<sup>2,3</sup> Martine Pagnard,<sup>2</sup> France Trevisan,<sup>2</sup> Isabelle Kemlin,<sup>4</sup> Diana Rodriguez,<sup>4,5</sup> and David Cohen<sup>2,6</sup>

<sup>1</sup>Department of Child and Adolescent Psychiatry, Robert Debré Hospital, Paris, France

<sup>2</sup>Department of Child and Adolescent Psychiatry, Reference Center for Rare Psychiatric Diseases, APHP, Groupe Hospitalier Pitié-Salpêtrière, Université Sorbonne, Paris, France

<sup>3</sup>GRC-15, Approche Dimensionnelle des Épisodes Psychotiques de l'enfant et de l'adolescent, Faculté de Médecine, UPMC, Sorbonne Universités, Paris, France

<sup>4</sup>Centre de Référence des Neurofibromatoses et Service de Neurologie Pédiatrique, AP-HP, Hôpital Armand Trousseau, GHUEP, Paris, France

<sup>5</sup>Sorbonne Université, Hôpital Armand Trousseau, F-75012, Paris, France

<sup>6</sup>Institut des Systèmes Intelligents et Robotiques, CNRS, UMR 7222, Université Sorbonne, Paris, France

Correspondence should be addressed to Ana Moscoso; [anamoscoso@yahoo.com](mailto:anamoscoso@yahoo.com)

Received 23 May 2019; Accepted 27 November 2019; Published 31 December 2019

Academic Editor: Erik Jönsson

Copyright © 2019 Ana Moscoso et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Introduction.** Cognitive and behavioural problems associated with Neurofibromatosis type 1 (NF1) are common sources of distress and the reasons behind seeking help. Here we describe patients with NF1 or NF1-like phenotypes referred to a Tier 3 Child and Adolescent Psychiatry Department and highlight the benefits of a multidisciplinary assessment. **Methods.** Prospective data were gathered from NF1 patients aged 7–15 years, referred by the NF1 Referral Centre due to additional difficulties either in management or diagnosis. For the selected cases, we performed a psychiatric assessment, a tailored neuropsychological evaluation based on clinical demands and history, broad speech and motor skills evaluations if there were concerns regarding language, motor abilities and/or learning difficulties and autism specific evaluations, if clinically relevant. No exclusion criteria were applied. **Results.** Complex NF1 cases represented only 5% of the patients (11/224). Assessments revealed the complexity of NF1 phenotype and a variety of problems including learning difficulties, emotional problems and autism spectrum disorders. Specific evaluations of language, motor, attentional and neurovisual domains were essential to guide tailored intervention strategies. **Conclusions.** In terms of clinical implications, the heterogeneity of NF1 phenotypical manifestations needs to be considered when developing assessment and remediation approaches for children with complex NF1.

## 1. Background

Neurofibromatosis type 1 (NF1) affects approximately 1/3,000 individuals worldwide [1]. Diagnostic criteria are varied and include *café-au-lait* spots, neurofibromas, freckling of the axillary or inguinal regions, optic glioma, Lisch nodules, distinctive osseous lesions (such as sphenoid dysplasia or thinning of long bone cortex), as well as having a first-degree relative evidencing NF1 symptoms as detailed above [2].

Although NF1 is an autosomal dominant condition (familial type), de novo mutations account for up to 50% of the cases (sporadic type). *NF1* is completely penetrant, nonetheless it exhibits variable clinical expressivity, even between family members with the same *NF1* mutation [3]. Most *NF1* mutations result in reduced intracellular levels of the protein neurofibromin, leading to excessive cell proliferation, including development of neurofibromas and tumours and diminished cognitive capacity [4].

In clinical practice, cognitive and behavioural problems associated with NF1 and their impact on academic performance is a common source of distress and the reason behind seeking help in child psychiatry. Indeed, between 30% and 70% of individuals with NF1 have learning disabilities concerning speech, reading, writing, spelling and mathematics. These problems represent the most significant cause of lifetime morbidity associated with the disease [5, 6]. Even though some phenotypic patterns have been suggested in the past, a more in-depth analysis reinforces the need to tailor the diagnosis and the treatment of these patients.

The global cognitive functioning of NF1 patients is usually preserved, although somewhat lower when compared to unaffected siblings or peer groups [7]. Intellectual disability, defined clinically as an intelligence quotient (IQ) lower than 70 in cognitive evaluations, is estimated to be around 4–8% in NF1 patients vs. 2–3% in the general population [8, 9]. However, the exclusion of patients with central nervous system (CNS) pathology from cohort studies of NF1 prevalence reduces the number of patients with clinically moderate to severe NF1 [8] and may underestimate the prevalence of intellectual disability amongst this population.

For many years the Child and Adolescent Psychiatry Department of Pitié-Salpêtrière has been treating paediatric patients who present neuropsychiatric symptoms of rare diseases [10–12] as examples. As a specialised team, the department receives complex patients which present significant management issues. NF1 patients are referred to this department. Here we describe patients with NF1 received in our Department and highlight the benefits of a multidisciplinary assessment.

## 2. Methods

**2.1. Patients.** Prospective data were gathered from NF1 patients (NIH, 1988) aged 7–15 years, referred by the Neurofibromatosis Referral Centre at Trousseau Paediatric Hospital for evaluation at the Department of Child and Adolescent Psychiatry at University Hospital La Pitié-Salpêtrière. The data spans from 2009 until 2016. The procedures regarding the assessments and follow-ups at the Referral Centre are described elsewhere [13]. Referrals were made due to additional difficulties either in management or diagnosis of patients and represented only a small part of the cohort (11/224—approximately 5%). No exclusion criteria were applied as we wanted to describe all complex aspects of this clinical sub sample.

**2.2. Procedures and Instruments.** Patients were assessed in medical consultations and further comprehensive evaluations. For the selected cases, we extracted from the prospective database: sociodemographic data (age, sex, academic level); all relevant information from the semi-structured medical interview to evaluate the patient's personality and family history of psychiatric and medical disorders, including NF1 clinical features, complications and follow-ups; and all relevant biological (e.g. genetic testing), physiological (e.g. electro-encephalography) and imaging (e.g. magnetic resonance imaging) information. In addition, we performed

(1) a psychiatric assessment; (2) a tailored neuropsychological evaluation (e.g. executive function, attention, memory, neurovisual) based on clinical demands and history; (3) a broad speech evaluation, if there were language (oral and/or written) concerns or learning difficulties; (4) a global and fine motor skills evaluation, if there were concerns regarding motor abilities and/or learning difficulties (such as difficulties to write), and (5) autism specific evaluations, if clinically relevant. The list of testing is given in Tables 1 and 2.

Evaluations were performed because they had clinical relevance. They were adapted to the needs and characteristics of each patient. Medical files containing clinical data were thoroughly explored (AM, AJ, MP) and relevant data were included (AM, AJ, AT, MP). Psychiatric diagnoses were made according to DSM-5 criteria. Finally, the scores obtained in neuropsychological, speech and fine motor skills assessments were converted into standard deviations in order to have unique common statistics and to ease presentation.

## 3. Results

Eleven patients were included. All, except one, were boys with a mean age of 10.6 (range 7–15) years. Five patients had a first degree relative with NF1 (father, mother or sibling). Two patients lived in foster care and five with one parent (due to divorce). One had Legius syndrome, a genetic condition associated with *sprouty related EVH1 domain containing 1 (SPREAD1)* gene mutation, which phenotype overlaps that of NF1 [14]. For clarity, we present the patients in two separate tables. Table 1 summarises the clinical profile of four NF1 patients with an intellectual deficiency and Table 2 presents the profile of patients with subnormal IQ.

**3.1. Reasons for Referral.** Patients came with multiple and diverse complaints. Reasons for referral included learning difficulties (due to the consequences of instrumental difficulties, suspicion of attention deficit hyperactivity disorder (ADHD) or intellectual disability;  $N = 7$ ), or emotional problems or suspicion of emergent psychopathology ( $N = 6$ ). A few ( $N = 4$ ) were referred because of autism spectrum disorder (ASD) (doubts regarding diagnosis or difficulties in clinical management).

**3.2. NF1 Clinical Characteristics and Intellectual Impairment.** Clinical complications of NF1 (skeletal, vascular, malignancy, epilepsy, precocious puberty, the presence of unidentified bright objects (UBOs) in CNS) were present in patients who also had a certain degree of intellectual disability (Table 1), sometimes accompanied by autistic features (patients 1, 2, 4; Table 1). Only, one patient with NF1 complications did not present with an intellectual disability but had a borderline IQ (patient 8; Table 2). In four patients, UBOs were present mainly in the cerebellum and the basal ganglia (patients 1, 2, 4 and 8). NF1 complications motivated frequent medical appointments and hospitalisations, an additional burden for patients and their families. For all the other patients (Table 2) only mild NF1 features, such as café-au-laits spots,

TABLE 1: Clinical profile of NF1 patients with an intellectual deficiency.

	Patient 1	Patient 2	Patient 3	Patient 4
Sex, age	Male, 12 years	Male, 13 years	Male, 15 years	Female, 8 years
Main reasons for referral	Increasing puberty-onset aggressiveness Suspicion of ADHD Inpatient unit	ASD assessment Suspicion of ADHD Outpatient unit	Psychiatric assessment in the context of sexual assault Outpatient unit	Suspicion of ADHD Social problems (foster care) Outpatient unit
NF1 diagnosis	Familial NF1 (including intellectual disability)	Sporadic NF1 Additional genetic research was negative: karyotype, x fragile	Familial NF1	Familial NF1
NF1 complications	Dystrophic thoracic scoliosis Sphenoid bone dysplasia Labile renovascular hypertension Intermittent claudication Several complicated surgical interventions/hospitalisations Absence of pheochromocytoma or precocious puberty UBOs: bilateral temporal; right lentiform nucleus; cerebellum/protuberance Vineland (age 4): developmental delays ranging from 7–39 months (Repeated gastroenteritis during childhood)	Sphenoid bone dysplasia Orbicular-facial plexiform neurofibroma (surgically removed) UBOs: basal ganglia, cerebellum	Bilateral optic pathway tumor, remission	Optic pathway tumor, remission Precocious puberty Epilepsy UBOs: left pallidum, white matter
Developmental delay (early history)		Hypoxia at birth (Repeated gastroenteritis during childhood)	Blindness	Prematurity PEP-R (age 3): Average developmental delay 11–13 months
Cognitive assessment	TERMAN–MERRILL Moderate intellectual disability	PEP-3: mild intellectual disability Divided attention TEA-Ch: –2.6SD Unimodal attention TEA-Ch –2.6SD Language EXALANG: delays in all domains (oral/written) (average: –1.7SD) Flexibility NEPSY-II: –1.4SD Working memory NEPSY-II: –1.4SD	Assessment not available	BRUNET-LEZINE (age 3): Developmental delays ranging from 8–14 months
ASD assessment	CARS (age 4) = 30.5 (mild autism) ADI-R: stereotypies = 9 (threshold 3) Communication domain = 14 (threshold 8) Other: anxiety	Clinical evaluation: repetitive behaviors and perseverant thoughts Deficits in social cognition/pragmatics: EMOTION COMPREHENSION TEST – 1.3SD	No clinical suspicion	ADOS Communication domain = 6 (threshold 4) Social interaction = 14 (threshold 7)

TABLE 1: Continued.

	Patient 1	Patient 2	Patient 3	Patient 4
Psychiatric diagnosis	Moderate intellectual disability Autism Dyspraxia NF1 related stress (comorbidities) No criteria for ADHD	Mild intellectual disability Autism Dyspraxia ADHD-hyperkinetic type	Mild intellectual disability	Moderate intellectual disability Autism Dyspraxia NF1 related stress (comorbidities) ADHD-hyperkinetic type <small>CONNERS; clinical assessment</small>
Medication	Aripiprazole Melatonin Labetalol Clonidine	Methylphenidate  Melatonin	None	Levetiracetam Enantone Methylphenidate Risperidone Melatonin
Nonpharmacological treatment	Full time school for disabled adolescents, including remediation to improve attention, speech, motricity Regular follow-up Regular multidisciplinary discussion	Full time school for autistic adolescents Adapted school activities, including remediation to improve attention	Full time school for disabled adolescents Regular psychiatric follow up	Full time school for disabled children, including remediation to improve attention, speech, motricity. Foster family
Outcome	Clinical improvement Balancing day-to-day life with the ongoing co-morbidities of NF1 is a challenge to him and his family	Stable	Improvement	Improvement (less than expected due to social difficulties) Balancing day-to-day life with the ongoing co-morbidities of NF1 is a challenge to her

ADHD, attention deficit hyperactivity disorder; ADI-R, autism diagnostic interview-Revised [15]; ADOS, autism diagnostic observation schedule [16]; ASD, autism spectrum disorder; BRUNET-LEZINE, First childhood psychomotor developmental schedule [18]; CARS, The childhood autistic rating scale [19]; CONNERS, Conner's continuous performance test [20]; EMOTION COMPREHENSION TEST, Test of emotion comprehension [27]; EXALANG, language evaluation for children 8–11 years [21]; NEPSY-II, Neuropsychological test for children [22]; NF1, Neurofibromatosis type 1; PEP, Psychoeducational profile: Revised (PEP-R) and third edition (PEP-3) [23]; TEA-Ch, test of everyday attention for children [24]; TERMAN-MERRILL, Stanford-Binet intelligence scale [25]; UBOS, unidentified bright objects; VINELAND, adaptive behaviour scales [28].

TABLE 2: Clinical profile of NFI patients with subnormal IQ.

	Patient 5	Patient 6	Patient 7	Patient 8	Patient 9	Patient 10	Patient 11
Sex, age	Male, 10 years	Male, 8 years	Male, 8 years	Male, 9 years	Male, 15 years	Male, 7 years	Male, 12 years
Learning difficulties	Learning difficulties	Learning difficulties	Learning difficulties	Intermittent explosive behaviour; ADHD	Confirmation of ASD (ADOS-ADI-R)	Suspicion of ADHD	Mood disorder
Main reason for referral	Anxiety symptoms	Behavioural difficulties	Hyperactivity sleep; family related issues	NFI complications: Precocious puberty; nondysplastic scoliosis; UBOs: cerebellum, <i>globus pallidus</i>	Emotional lability	NFI related stress	Learning difficulties
Social difficulties	Social difficulties						
NFI diagnosis	Outpatient unit	Outpatient unit	Outpatient unit	Outpatient unit	Outpatient unit	Outpatient unit	Outpatient unit
	Familial NFI	Familial NFI	Sporadic NFI	Sporadic NFI	Sporadic NFI	Sporadic NFI	Legius SD
Developmental delay	Minor (graphic abilities)	No	Minor (global motor)	Walking unstable at 21 months	???	No	Not reported
	Repeated otitis		Prematurity	Speech delay (Repeated otitis)			
Cognitive assessment	Verbal: 92; performance: 121; working memory: 97; speed: 88	Verbal: 86; performance: 77; working memory: 73; speed: 71	Verbal: 92; performance: 94; working memory: 76; speed: 78	Verbal: 98; performance: 65; working memory: 82; speed: 83	Verbal: 86; performance: 73; working memory: 109; speed: 100	Verbal: 92; performance: 109; working memory: 91; speed: 103	Verbal: 94; performance: 90; working memory: 73; speed: 66
WISC-IV	Heterogeneous	Heterogeneous	Heterogeneous	Heterogeneous	Heterogeneous	Heterogeneous	Heterogeneous
Attention and executive functions	Divided attention <sup>TEA-Ch</sup> ; -2SD	Divided attention <sup>TEA-Ch</sup> ; -1.4SD	Divided attention <sup>TEA-Ch</sup> ; Normal	Divided attention <sup>TEA-Ch</sup> ; -0.5SD	Divided attention <sup>TEA-Ch</sup> ; +0.7SD	Divided attention <sup>TEA-Ch</sup> ; +0.3SD	Unimodal attention <sup>TEA-Ch</sup> ; -0.7SD
	Unimodal attention <sup>TEA-Ch</sup> ; Normal	Unimodal attention <sup>TEA-Ch</sup> ; -1.4SD	Unimodal attention <sup>TEA-Ch</sup> ; Normal	Unimodal attention <sup>TEA-Ch</sup> ; -0.7SD	Unimodal attention <sup>TEA-Ch</sup> ; -0.7SD	Unimodal attention <sup>TEA-Ch</sup> ; +0.3SD	Unimodal attention <sup>TEA-Ch</sup> ; -0.7SD
	Sustained attention <sup>TEA-Ch</sup> ; -1.7SD	Sustained attention <sup>TEA-Ch</sup> ; -1.7SD	Attention control <sup>TEA-Ch</sup> ; +0.7SD	Attention control <sup>TEA-Ch</sup> ; +0.7SD	Attention control <sup>TEA-Ch</sup> ; +0.7SD	Attention control <sup>TEA-Ch</sup> ; +0.7SD	Attention control <sup>TEA-Ch</sup> ; +0.7SD
	Inhibition <sup>TEA-Ch</sup> ; -2SD	Inhibition <sup>TEA-Ch</sup> ; -2SD	Inhibition <sup>TEA-Ch</sup> ; -2SD	Inhibition <sup>TEA-Ch</sup> ; -2SD	Inhibition <sup>TEA-Ch</sup> ; -2SD	Inhibition <sup>TEA-Ch</sup> ; -2SD	Inhibition <sup>TEA-Ch</sup> ; -2SD
	Flexibility <sup>NEPSY-II</sup> ; -0.1SD	Flexibility <sup>NEPSY-II</sup> ; -1.5SD	Flexibility <sup>NEPSY-II</sup> ; -0.5SD	Flexibility <sup>NEPSY-II</sup> ; -1.5SD	Flexibility <sup>NEPSY-II</sup> ; -1.4SD	Flexibility <sup>NEPSY-II</sup> ; -0.1SD	Flexibility <sup>NEPSY-II</sup> ; -0.2SD
	Short-term <sup>NEPSY-II</sup> ; -0.1SD	Short-term <sup>NEPSY-II</sup> ; -1.2SD	Short-term; -1.6SD	Short-term <sup>NEPSY-II</sup> ; -0.3SD	Short-term <sup>NEPSY-II</sup> ; -0.3SD	Short-term <sup>NEPSY-II</sup> ; -0.7SD	Short-term <sup>NEPSY-II</sup> ; -0.3SD
Memory	Episodic <sup>REV</sup> ; -0.3SD	Episodic <sup>REV</sup> ; +0.5SD	Episodic <sup>REV</sup> ; +0.5SD	Episodic <sup>REV</sup> ; +0.5SD	Episodic <sup>REV</sup> ; +0.4SD	Episodic <sup>REV</sup> ; +0.4SD	Episodic <sup>REV</sup> ; -3SD

TABLE 2: Continued.

	Patient 5	Patient 6	Patient 7	Patient 8	Patient 9	Patient 10	Patient 11
Language assessment EXALANG	Oral receptive: -0.7SD Oral expressive: -0.5SD Oral lexicon: +0.7SD Written receptive: -2.6SD Written expressive: -2.9SD Spelling: -2.6SD	Oral receptive: -1.5SD Oral expressive: -2SD Oral lexicon: -1.2SD Written expressive: -1.7SD	Oral expressive: +1.4SD Oral lexicon: -0.5SD Written receptive: +1.4S Written expressive: -0.5SD	Normal	Normal	Normal	Oral lexicon: -1.3SD Written expressive: -2.6
Motricity	Visuo-construction <sub>REV</sub> : +0.5SD Visuo-spatial <sub>NEPSY-II</sub> : +0.5SD Graphomotor skill <sub>BHK</sub> : -2.3SD	Visuo-construction <sub>REV</sub> : Normal Visuo-spatial <sub>NEPSY-II</sub> : -0.6SD Graphomotor skill <sub>BHK</sub> : -2SD	Visuo-construction <sub>REV</sub> : -0.7SD Visuo-spatial <sub>NEPSY-II</sub> : -0.3SD Graphomotor skill <sub>BHK</sub> : -2SD	Visuo-construction <sub>REV</sub> : -3SD Visuo-spatial <sub>NEPSY-II</sub> : -0.1SD Graphomotor skill <sub>BHK</sub> : -2SD	Visuo-construction <sub>REV</sub> : -0.3SD Visuo-spatial <sub>NEPSY-II</sub> : -0.8SD Graphomotor skill <sub>BHK</sub> : +1.4SD	Visuo-construction <sub>REV</sub> : +0.2SD Visuo-spatial <sub>NEPSY-II</sub> : +0.3SD Graphomotor skill <sub>BHK</sub> : +0.4SD	Visuo-construction <sub>REV</sub> : -0.7SD Visuo-spatial <sub>NEPSY-II</sub> : -0.8SD Graphomotor skill <sub>BHK</sub> : -0.3SD
Socio-cognition/pragmatic	-0.7SD	-0.3SD	-0.3SD	-2.2SD	-1SD	Normal	Normal
Psychiatric Diagnosis	ADHD-inattentive type Dyslexia Pragmatic communication disorder	Borderline intelligence ADHD-impulsive type Dysexecutive profile At risk for dyslexia	Anxious disorder Motor (graphic) delay	Borderline intelligence ADHD, ODD Visual-Spatial Dyspraxia Dysgraphia	ASD (Asperger) Dysexecutive profile Dyspraxia	Anxiety disorder	Mood disorder Attachment disorder Written language difficulties NFI related stress
Medication	Methylphenidate Specific school adaptations	Methylphenidate (not well tolerated) Specific school adaptations	Melatonin	Methylphenidate Triptorelin Acetate Specific school adaptations	Aripiprazole Specific school adaptations	None	Quetiapine
Nonpharmacological treatment	Speech and reading therapy Motor skills remediation	Speech and reading therapy Motor skills remediation	Motor skills remediation Psychotherapy	Speech and reading therapy (past) Motor skills remediation Psychodrama therapy	Language and motor remediation in the past Social strategies group	Speech and reading therapy	Speech and reading therapy
Outcome	Improvement	Improvement	Stable	Improvement	Stable	Stable	Psychiatric follow-up Stable

ADHD, attention deficit hyperactivity disorder; ADI-R, autism diagnostic interview-Revised [15]; ADOS, autism diagnostic observation schedule [16]; ASD, autism spectrum disorder; BHK, concise evaluation scale for children handwriting [17]; EMOTION COMPREHENSION TEST, Test of emotion comprehension [27]; EXALANG, language evaluation for children 8-11 years [21]; NEPSY-II, Neuropsychological test for children [22]; NFI, Neurofibromatosis type 1; ODD, oppositional defiant disorder; TEA-Ch, test of everyday attention for children [24]; REY, Rey's complex figure test [25]; UBOs, unidentified bright objects; WISC IV, the Wechsler intelligence scale for children [29].

intertriginous freckling, few neurofibromas and/or Lisch nodules, were present. These patients all had subnormal IQ.

**3.3. NF1 and Learning Disabilities.** All patients had learning disabilities that appeared as a primary or secondary cause of referral. For the patients who had subnormal IQ scores (Table 2), it was common to find discrepancies in IQ subscales. Within each subscale, scores could vary widely (data not shown). Even if the patients received an *average/mean* IQ, their global intellectual efficiency was weaker when compared to the general population.

Specific learning disabilities were also common. They included specific language developmental delays (patients 5, 6, 9, 11; Table 2), graphomotor delays (patients 5, 6, 7, 8; Table 2) and developmental coordination disorders (dyspraxia) (patients 8, 9; Table 2). Some patients also had comorbid ADHD (patients 5, 6, 8; Table 2). The extensive developmental evaluation was crucial to disentangle diagnosis and also to guide further therapeutic propositions. Such specific propositions included school adaptations (such as having more time to finish evaluations, the use of computer to write), speech and reading therapies once or twice per week, and motor skills remediation once per week, that lead to improvement (non-pharmacological treatment; Table 2).

Patients with intellectual disabilities (Table 1) arguably presented learning difficulties. Standard tests for cognitive evaluation (such as the Wechsler intelligence scale for children, WISC [29]) were difficult to perform in such patients. In these cases, clinical evaluation and developmental scales were helpful (Brunet Lezine [18]), Terman Merrill [25]), as well as some psychosocial scales (Psychoeducational Profile (PEP) [23], Vineland [28]) that estimate performance in more ecologic day to day activities. In this context, specific evaluations of language, motor, and attentional domains are equally important to guide tailored intervention strategies. Intervention strategies were generally more global in the context of schooling for disabled children.

**3.4. NF1 and Attentional Issues.** Four of our patients had an ADHD diagnosis, obtained after clinical assessment and a specific neuropsychological evaluation (Test of Everyday Attention for Children, TEA-Ch [24]). A fifth patient (patient 4; Table 1) diagnosed with ADHD was evaluated through clinical observation and functional scales (Conners [20]), because the neuropsychological evaluation was difficult to perform given the intellectual deficit. In all cases, an ADHD diagnosis was made along with other comorbidities and was never isolated. Four patients were treated with methylphenidate and one was given specific cognitive training addressing attention. Three patients receiving methylphenidate improved and one stopped the treatment due to side effects.

**3.5. NF1, Emotional Problems and Emergent Psychopathology.** The most frequent diagnosis was anxiety disorder and/or NF1 related stress (patients 1, 4, 7, 10, 11). Two visited for the evaluation and treatment of mood disturbances (patients 8, 11; Table 2). Finally, another patient visited for psychiatric evaluation in the context of sexual assault (patient 3; Table 1). Medication along with nonpharmacological

treatments such as different types of psychotherapy were proposed and appeared to be helpful.

**3.6. NF1 and Autistic Spectrum Symptomatology.** Four patients presented clear autistic features after clinically comprehensive/developmental assessment and additional assessment tools (patients 1, 2, 4; Table 1 and patient 9, Table 2). Three patients with autistic features had concurrent intellectual disability (Table 1). A fifth patient with an ongoing history of social difficulties had a pragmatic communication disorder (patient 5; Table 2). Complementary psychological tests were helpful for the diagnosis (CARS [19], ADI [15], ADOS [16]). Treatment strategies addressed co-morbidities as well as core features of autism (e.g., social strategies in group) in outpatient settings or in the context of specific schooling models.

## 4. Discussion

This case series reflects the variety of problems and the complexity of severe NF1 paediatric patients. The gender bias reflected in our sample may result from the overrepresentation of boys in child and adolescent psychiatry consultations and therefore will not necessarily reflect the epidemiology of NF1 [30]. Also, the morbimortality of the disease, is mild to moderate in most cases. Nonetheless, clinical complications of NF1 can present a serious burden. This was the case for most of the patients reported here, who were referred to a special psychiatric clinic for rare diseases. The large heterogeneous phenotypic expression of NF1 is likely to be a consequence of the stochastic chain of events associated with NF1. At a molecular level, the reduced intracellular levels of neurofibromin found in NF1 patients induce impairments in learning and memory through imprecise, i.e. abnormally high or low RAS modulation and consequential gamma-aminobutyric acid (GABA)-mediated excessive inhibition in the hippocampus [4, 31]. Also, patients with NF1 may show subcortical unidentified bright objects (UBOs) as we found in four of our patients. In all but one, UBOs were present in patients with intellectual disability and a multitude of somatic complications of the disease. UBOs are present in approximately 60–70% [32, 33] of the children with NF1 but tend to disappear with age. Histopathologic studies have shown that UBOs correspond to areas of myelin vacuolization with increased water content [34] and therefore, could reflect disordered myelination [35]. The presence of UBOs has been associated with lower intellectual ability [36, 37] and also visuospatial impairments when UBOs were located in the cerebellum [38]. The latter seems to be the case for patients 1 and 2 (Table 1) and patient 8 (Table 2) in our case series.

**4.1. NF1 Cognitive Impairment and Learning Disabilities.** In this case series, the patients presented either a degree of intellectual disability (Table 1) or an average but heterogeneous cognitive profile with significant functional impairments (Table 2). Many studies have now made clear how intelligence is only mildly affected in the vast majority of NF1 patients. However, specific impairments in cognition are very common (up to 80% of children in NF1 clinics [8]) and have a negative

impact in the quality of life. Some specific deficits have been reported to NF1: visual-spatial deficits [39], speech and language deficits, motor skill deficits [40], social skill deficits [5, 41] and attentional deficits [8, 42]. All may lead to learning disabilities and further emotional suffering. The presence of visual-spatial and attentional deficits has been robustly replicated [7, 43]. However, research has revealed contradictory results regarding motor skills and language performance in patients with NF1 [7]. Moderate to severe intellectual disability and severe clinical cases seemed to be the focus of interest of early works in neurofibromatosis [44] but severe cases of NF1 have received little attention recently.

**4.2. NF1 and ADHD.** In all our NF1-ADHD patients, the ADHD diagnosis was made along with other comorbidities and was never isolated. Patients with NF1 present more symptoms and are more often diagnosed with ADHD than the general population. Prevalence estimates range from 30% to 50% [45, 46], which are higher than those expected in the general population, i.e. about 5% in children and 2.5% in adults [47, 48].

Clinical and cognitive profiles of both ADHD patients with and without NF1 are heterogeneous. Individuals are affected in different domains of attention, impulsivity, hyperactivity and executive functioning, and to different degrees [46, 49]. Visual attention seems consistently impaired in NF1 patients [50, 51] and would lead to instability in focusing attention and lower resistance to interference in controlled tasks but also to inattentive and impulsive behaviour in natural environments.

Importantly, ADHD-NF1 patients seem responsive to methylphenidate [42, 46]. This improvement has been also reported for children with IQs lower than 80 [46]. In our case series, four of the patients diagnosed with ADHD were treated with methylphenidate, three showing a great improvement and one dropping out of treatment due to side effects.

The high frequency of ADHD in children with NF1, as well as the demonstrated significant comorbidity of ADHD with literacy learning disabilities [8] and social skills problems [52] indicates the need for thorough screening of ADHD symptomatology in all children with NF1 [45]. Besides, the impact of attention deficits and behaviour problems in children with NF1 often leads to lower social acceptance and lack of self-confidence/esteem. When emotional problems are secondary to ADHD, effective treatment of ADHD can improve them both [46].

**4.3. NF1 and Autistic Spectrum Symptomatology.** After some early work evoking associations between autism and NF1 [53] there is a re-enacted concern regarding ASD and NF1. Since Huijbregts and de Sonnevile [54] showed that NF1 impairments in cognitive control (i.e. a combination of processing speed, working memory, inhibitory control, and emotional processing functions) is associated with the presence of autistic traits, several studies have explored the prevalence of ASD symptoms in NF1 populations.

Studies focusing on social impairments as a continuous variable within the social responsiveness scale (SRS) [55–58] showed that NF1 patients present more social impairments

than the general population (up to 40% in some samples [56]). Whether or not this is enough to state that ASD is increased in NF1 patients is another question. First, ASD screening tools are not meant to provide a diagnosis of ASD, but rather identify children who should be further evaluated. Second, NF1 patients with high SRS scores show mild to moderate ASD symptomatology (e.g. latter diagnosis during school years; no stereotyped behaviours) [57]. We believe that research should explore further the meaning of ASD symptomatology in NF1. Given the rarity of stereotyped behaviours in NF1, perhaps the DSM-5 diagnosis of social communication disorder will be more appropriate in some cases? Also, is it legitimate to use SRS score as a continuous variable? Indeed, when re-analysing the largest cohort of NF1 so far that reported SRS scores [59] we found that the best model to predict data distribution using admixture analysis was a bimodal distribution (Figure 1), with a large group of patients with a mean SRS score equal to 55 (red curve), and a smaller group of patients with a higher mean SRS score equal to 70 (green curve). This means that considering SRS as a continuous variable showing a normal distribution may be inappropriate. This also means that NF1 phenotype heterogeneity might be better understood separating subgroups of patients as it has been shown in other genetically complex neurodevelopmental disorders.

However, we do believe that rare typical cases of ASD can also be encountered in NF1. Three patients in this case series presented an unequivocal profile of ASD comorbid with intellectual disability. Several authors postulated that autism associated with neurogenetic syndromes can be classified as “complex autism” or “syndromic autism” [60–62]. Complex autism is characterised by lower IQ, higher rates of comorbidities both psychiatric and somatic, and higher rates of epilepsy [63, 64]. For these severe cases, this classification may be useful to better explore their clinical profile and tailor treatment to the child’s needs [65].

**4.4. NF1 and Emotional Problems.** NF1 has also significant social and psychological consequences on individuals and their families [66, 67]. Most patients of this case series were referred with emotional problems. While some ( $n = 7$ ) had behavioural difficulties (sometimes secondary to ADHD or to learning disabilities), others expressed internalising symptoms such as anxiety or depression. These conditions can often be found in NF1 [67]. The emotional impact of cosmetic deformities, the fear of malignancy, and the medical complications, such as the management of hypertension or the need for surgical interventions should be carefully evaluated and not be neglected. Learning difficulties can also generate feelings of low self-esteem and inefficiency that can last in time. In addition, the impact of attention deficits and behaviour problems in children with NF1 often leads to lower social acceptance and lack of self-confidence. As mentioned previously, when emotional problems are secondary to ADHD, effective treatment of ADHD can improve them both [46]. Besides, parents of NF1 children experience greater stress than other parents [68], sometimes associated with feelings of guilt regarding the genetic transmission of NF1. The parents should also receive proper care.






FIGURE 1: Theoretical distribution of social responsiveness scale (SRS) scores in individuals with NF1 ( $n = 412$ ). The admixture analysis shows that the best fitting model for SRS scores in NF1 finds 2 subgroups with low and high scores (mean SRS = 55 (red curve) and 70 (green curve), respectively). Data from Morris et al. [59].

**4.5. Treatment Modalities and Outcome.** Strategies that decrease either RAS activity or GABA-mediated inhibition have been suggested to specifically treat learning and emotional deficits associated with NF1. Pharmacologically targeting this pathway with an HMG-CoA reductase inhibitor (an anti-RAS agent), such as lovastatin [69] evidenced some encouraging results in animal models. However, to date, clinical trials with NF1 patients have shown modest results [70–72]. Therefore, current treatment options remain symptomatic. The heterogeneity of NF1 phenotypical manifestations needs to be considered when developing assessment and remediation approaches for children with NF1. The outcome is therefore variable, different for each patient.

## 5. Conclusions

In severe cases of NF1 with important psychiatric morbidity, it can sometimes be difficult to disentangle specific domains of impairment, as cognition as a whole is complex. In day-to-day activities, more than one cognitive domain is needed to perform adequately, making the task of disentanglement even more challenging. This is why a multidimensional and longitudinal clinical evaluation is warranted when assessing patients.

Phenotype-genotype correlations tend to subscribe the idea that behavioural manifestations present themselves with continuous variation. This type of pattern was proposed for NF1 autistic symptoms [59]. However, we believe that more complex phenotype/genotype association occurs in NF1 for psychiatric comorbidity including ASD symptomatology. Similarly to other genetic conditions such as juvenile myotonic dystrophy [73], or tuberous sclerosis [74], bimodal phenotypic patterns of intelligence/cognitive performance seem to adapt better to the distribution of IQ scores in these populations. In terms of clinical implications, the heterogeneity of NF1 phenotypical manifestations needs to be considered when developing assessment and remediation approaches for children with NF1.

## Conflicts of Interest

The authors declare that they have no conflicts of interest.

## Acknowledgements

The authors wish to thank Joana Queiroz for the English language-editing.

## References

- [1] J. M. Friedman, "Epidemiology of neurofibromatosis type," *American Journal of Medical Genetics*, vol. 89, no. 1, pp. 1–6, 1999.
- [2] D. A. Stumpf, "Neurofibromatosis. conference statement, national institutes of health consensus development conference," *Archives of Neurology*, vol. 45, no. 5, pp. 575–578, 1988.
- [3] K. P. Boyd, B. R. Korf, and A. Theos, "Neurofibromatosis type 1," *Journal of the American Academy of Dermatology*, vol. 61, pp. 1–16, 2009.
- [4] R. M. Costa, N. B. Federov, J. H. Kogan et al., "Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1," *Nature*, vol. 415, no. 6871, pp. 526–530, 2002.
- [5] S. R. Plotkin, A. C. Albers, D. Babovic-Vuksanovic et al., "Update from the 2013 international neurofibromatosis conference," *American Journal of Medical Genetics. Part A*, vol. 164, no. 12, pp. 2969–2978, 2014.
- [6] J. C. Isenberg, A. Templer, F. Gao, J. B. Titus, and D. H. Gutmann, "Attention skills in children with neurofibromatosis type 1," *Journal of Child Neurology*, vol. 28, no. 1, pp. 45–49, 2013.
- [7] A. Lehtonen, E. Howie, D. Trump, and S. M. Huson, "Behaviour in children with neurofibromatosis type 1: cognition, executive function, attention, emotion, and social competence," *Developmental Medicine and Child Neurology*, vol. 55, no. 2, pp. 111–125, 2012.
- [8] S. L. Hyman, A. Shores, and K. N. North, "The nature and frequency of cognitive deficits in children with neurofibromatosis type 1," *Neurology*, vol. 65, no. 7, pp. 1037–1044, 2005.
- [9] R. E. Ferner, R. A. Hughes, and J. Weinman, "Intellectual impairment in neurofibromatosis 1," *Journal of the Neurological Sciences*, vol. 138, no. 1-2, pp. 125–133, 1996.
- [10] M. Douniol, A. Jacquette, D. Cohen et al., "Psychiatric and cognitive phenotype of childhood myotonic dystrophy type 1 includes internalising disorder, borderline intelligence, visual spatial construction disability and attention deficit disorder," *Developmental Medicine and Child Neurology*, vol. 54, no. 10, pp. 905–911, 2012.
- [11] O. Bonnot, D. Cohen, D. Thuilleaux, A. Consoli, S. Cabal-Berthoumieu, and M. T. Tauber, "Psychotropic treatments in Prader Willi syndrome: a critical review of published literature," *European Journal of Pediatrics*, vol. 175, no. 1, pp. 9–18, 2016.
- [12] A. Consoli, M. Raffin, C. Laurent et al., "Medical and developmental risk factors of catatonia in children and adolescents: a 17-year prospective study," *Schizophrenia Research*, vol. 137, pp. 151–158, 2012.
- [13] V. Coutinho, H. Câmara-Costa, I. Kemlin, T. Bilette de Villemeur, D. Rodriguez, and G. Dellatolas, "The discrepancy between performance-based measures and questionnaires when assessing clinical outcomes and quality of life in pediatric patients with neurological disorders," *Applied Neuropsychology: Child*, vol. 6, no. 4, pp. 255–261, 2017.
- [14] G. Spurlock, E. Bennett, N. Chuzhanova et al., "SPRED1 mutations (Legius syndrome): another clinically useful genotype for dissecting the neurofibromatosis type 1 phenotype," *Journal of Medical Genetics*, vol. 46, no. 7, pp. 431–437, 2009.
- [15] Le Couteur, A. C. Lord, and M. Rutter, *Autism Diagnostic Interview-Revised (ADI-R)*. Autism Genetic Resource Exchange, ADI-R, Los Angeles, CA, 2003.
- [16] C. Lord, M. Rutter, S. Goode et al., "Autism diagnostic observation schedule: a standardized observation of communicative and social behavior," *Journal of Autism and Developmental Disorders*, vol. 19, no. 2, pp. 185–212, 1989.
- [17] E. Hamstra-Bletz, J. D. Bie, and B. D. Brinker, "BHK—concise evaluation scale for children handwriting," *Beknopte Beoordelingsmethode Voor Kinderhandschriften (Une Méthode Rapide d'évaluation De L'écriture Chez L'enfant*, Swets & Zeitlinger, Lisse, 1987.
- [18] O. Brunet, I. Lézine, and D. Josse, "Le développement psychologique de la première enfance 1951. Nouvelle version révisée," *Echelle de Développement Psychomoteur De La Première Enfance*, E.A.P, PUF, Paris, 1997.
- [19] E. Schopler, R. J. Reichler, and B. R. Renner, *The Childhood Autism Rating Scale 1937*, Western Psychological Services, Los Angeles, 1988.
- [20] C. K. Conners, *Conners' Continuous Performance Test Version 5*, Pearson Canada Assessment, Toronto, 2 edition, 2004.
- [21] M. P. Thibault, M. Lenfant, and M. C. Helloin, "Bilan informatisé pour l'examen du langage et des compétences transversales chez l'enfant de 8 à 11 ans (ou scolarisé du CE2 au CM2)," 2003.
- [22] M. Korkman, U. Kirk, and S. Kemp, *NEPSY-II: Bilan Neuropsychologique De L'enfant [Neuropsychological Test for Children]. Bilan Neuropsychologique de l'Enfant (NEPSY)*, Edition du Centre de Psychologie Appliqué, Paris, 2 edition, 2012.
- [23] E. Schopler, R. J. Reichler, A. Bashford, M. D. Lansing, and L. M. Marcus, "Individual Assessment and Treatment for Autistic and Developmentally Disabled Children: Vol. 1," *Psychoeducational Profile Revised PEP*, Pro-Ed, USA, Austin, 3 edition, 1990.
- [24] T. Manly, V. Anderson, I. Nimmo-Smith, A. Turner, P. Watson, and I. H. Robertson, "The differential assessment of children's attention: the test of everyday attention for children (TEA-Ch), normative sample and ADHD performance," *Journal of Child Psychology and Psychiatry*, vol. 42, no. 8, pp. 1065–1081, 2001.
- [25] L. M. Terman, M. A. Merrill, and R. Samuel, *Stanford–Binet Intelligence Scale: Manual for the Third Revision Form L-M with Revised IQ Tables*, Houghton Mifflin, Pinneau. Boston (MA), 1960.
- [26] P. Wallon and C. Mesmin, *Test, de la figure complexe de Rey (Rey–Osterrieth complex figure): A. Rey Test de la figure complexe de Rey*, Edition du Centre de Psychologie Appliqué, Paris, 2009.
- [27] F. Pons, P. L. Harris, and M. de Rosnay, "Emotional comprehension between 3 and 11 years: developmental periods and hierarchical organization," *European Journal of Developmental Psychology*, vol. 1, no. 2, pp. 127–152, 2004.
- [28] S. S. Sparrow, D. A. Balla, D. V. Cicchetti, G. Balboni, and L. Pedrabissi, "Vineland Adaptive Behaviour Scales," *Circle Pines, MN: American Guidance Service, O.S.*, Florence, 2003.
- [29] D. Wechsler, *The Wechsler Intelligence Scale for Children—Fourth Edition*, Pearson, London, 2003.
- [30] H. C. Steinhouse, "Child and adolescent psychiatric disorders in a public service over seventy years," *European Child and Adolescent Psychiatry*, vol. 6, no. 1, pp. 42–48, 1997.
- [31] C. Li, Y. Cheng, D. A. Gutmann, and D. Mangoura, "Differential localization of the neurofibromatosis 1 (NF1) gene product, neurofibromin, with the F-actin or microtubule cytoskeleton during differentiation of telencephalic neurons," *Developmental Brain Research*, vol. 130, no. 2, pp. 231–248, 2001.

- [32] S. L. Hyman, D. S. Gill, E. A. Shores, A. Steinberg, and K. North, "T2-Hyperintensities in children with neurofibromatosis type 1 and their relationship to cognitive functioning," *Journal of Neurology, Neurosurgery and Psychiatry*, vol. 78, pp. 1088–1091, 2007.
- [33] J. R. Lopes Ferraz Filho, M. P. Munis, A. Soares Souza, R. A. Sanches, E. M. Goloni-Bertollo, and E. C. Pavarino-Bertelli, "Unidentified bright objects on brain MRI in children as a diagnostic criterion for neurofibromatosis type 1," *Pediatric Radiology*, vol. 38, no. 3, pp. 305–310, 2008.
- [34] D. P. DiPaolo, R. A. Zimmerman, L. B. Rorke, E. H. Zackai, L. T. Bilaniuk, and A. T. Yachnis, "Neurofibromatosis type 1: pathologic substrate of high-signal-intensity foci in the brain," *Radiology*, vol. 195, no. 3, pp. 721–724, 1995.
- [35] R. J. Sevick, A. J. Barkovich, M. S. Edwards, T. Koch, B. Berg, and T. Lempert, "Evolution of white matter lesions in neurofibromatosis type 1: MR findings," *AJR. American Journal Roentgenology*, vol. 159, no. 1, pp. 171–175, 1992.
- [36] P. Joy, C. Roberts, K. North, and M. de Silva, "Neuropsychological function and MRI abnormalities in neurofibromatosis type 1," *Developmental Medicine and Child Neurology*, vol. 37, no. 10, pp. 906–914, 1995.
- [37] J. M. Payne, T. Pickering, M. Porter et al., "Longitudinal assessment of cognition and T2-hyperintensities in NF1: an 18-year study," *American Journal of Medical Genetics. Part A*, vol. 164, no. 3, pp. 661–665, 2014.
- [38] O. Piscitelli, M. C. Digilio, R. Capolino, D. Longo, and V. Di Ciommo, "Neurofibromatosis type 1 and cerebellar T2-hyperintensities: the relationship to cognitive functioning," *Developmental Medicine and Child Neurology*, vol. 54, no. 1, pp. 49–51, 2012.
- [39] K. North, "Neurofibromatosis type 1," *American Journal of Medical Genetics*, vol. 97, no. 2, pp. 119–127, 2000.
- [40] A. B. Rietman, R. Oostenbrink, S. Bongers et al., "Motor problems in children with neurofibromatosis type 1," *Journal of Neurodevelopmental Disorders*, vol. 19, no. 9, p. 19, 2017.
- [41] E. I. Pierpont, R. L. Hudock, A. M. Foy et al., "Social skills in children with RASopathies: a comparison of Noonan syndrome and neurofibromatosis type 1," *Journal of Neurodevelopmental Disorders*, vol. 10, no. 1, p. 21, 2018.
- [42] L. Lion-François, F. Gueyffier, C. Mercier et al., "The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial," *Orphanet Journal of Rare Disorders*, vol. 9, no. 1, p. 142, 2014.
- [43] K. Lidzba, S. Granström, J. Lindenau, and V. F. Mautner, "The adverse influence of attention-deficit disorder with or without hyperactivity on cognition in neurofibromatosis type 1," *Developmental Medicine and Child Neurology*, vol. 54, no. 10, pp. 892–897, 2012.
- [44] N. Pinsard, M. Rufo, F. Giraud, and R. Bernard, "Mental retardation and Recklinghausen's neurofibromatosis," *Journal de Genetique Humaine*, vol. 23, pp. 228–229, 1975.
- [45] J. Payne, S. Hyman, E. Shores, and K. North, "Assessment of executive function and attention in children with neurofibromatosis type 1: relationships between cognitive measures and real-world behaviour," *Child Neuropsychology*, vol. 17, no. 4, pp. 313–329, 2011.
- [46] V. F. Mautner, L. Kluwe, S. D. Thakker, and R. A. Lark, "Treatment of ADHD in neurofibromatosis type 1," *Developmental Medicine and Child Neurology*, vol. 44, no. 3, pp. 164–170, 2002.
- [47] G. Polanczyk, M. S. de Lima, B. L. Horta, J. Biederman, and L. A. Rohde, "The worldwide prevalence of ADHD: a systematic review and meta-regression analysis," *American Journal of Psychiatry*, vol. 164, no. 6, pp. 942–948, 2007.
- [48] V. Simon, P. Czobor, S. Bálint, A. Mészáros, and I. Bitter, "Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis," *British Journal of Psychiatry*, vol. 194, no. 3, pp. 204–211, 2009.
- [49] L. J. Seidman, "Neuropsychological functioning in people with ADHD across the lifespan," *Clinical Psychology Review*, vol. 26, no. 4, pp. 466–485, 2006.
- [50] G. Michael, S. Garcia, V. Herbillon, and L. Lion-François, "Reactivity to visual signals in neurofibromatosis type 1: is everything ok?" *Neuropsychology*, vol. 28, no. 3, pp. 423–428, 2014.
- [51] M. J. Ribeiro, O. C. D'Almeida, F. Ramos, J. Saraiva, E. D. Silva, and M. Castelo-Branco, "Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits," *Journal of Neurodevelopmental Disorders*, vol. 6, no. 1, p. 4, 2014.
- [52] B. Barton and K. North, "Social skills of children with neurofibromatosis type 1," *Developmental Medicine and Child Neurology*, vol. 46, no. 8, pp. 553–563, 2004.
- [53] O. Mbarek, S. Marouillat, J. Martineau, C. Barthélémy, J.-P. Müh, and C. Andres, "Association study of the NF1 gene and autistic disorder," *American Journal of Medical Genetics*, vol. 88, no. 6, pp. 729–732, 1999.
- [54] S. C. Huijbregts and L. M. de Sonnevile, "Does cognitive impairment explain behavioral and social problems of children with neurofibromatosis type 1?" *Behavior Genetics*, vol. 41, no. 3, pp. 430–436, 2011.
- [55] S. Garg, A. Lehtonen, S. M. Huson et al., "Autism and other psychiatric comorbidity in neurofibromatosis type 1: evidence from a population-based study," *Developmental Medicine and Child Neurology*, vol. 55, no. 2, pp. 139–145, 2013.
- [56] K. S. Walsh, J. I. Vélez, P. G. Kardel et al., "Symptomatology of autism spectrum disorder in a population with neurofibromatosis type 1," *Developmental Medicine and Child Neurology*, vol. 55, no. 2, pp. 131–138, 2013.
- [57] E. Plasschaert, M. J. Descheemaeker, L. Van Eylen, I. Noens, J. Steyaert, and E. Legius, "Prevalence of Autism Spectrum Disorder symptoms in children with neurofibromatosis type 1," *American Journal of Medical Genetics Part B, Neuropsychiatric genetics*, vol. 168, no. 1, pp. 72–80, 2015.
- [58] J. Tinker, P. S. Carbone, D. Viskochil, A. Mathiesen, K. N. Ma, and D. A. Stevenson, "Screening children with neurofibromatosis type 1 for autism spectrum disorder," *American Journal of Medical Genetics. Part A*, vol. 164, pp. 1706–1712, 2014.
- [59] S. M. Morris, M. T. Acosta, S. Garg et al., "Disease burden and symptom structure of autism in neurofibromatosis type 1," *JAMA Psychiatry*, vol. 73, no. 12, pp. 1276–1284, 2016.
- [60] J. Miles, T. Takahashi, S. Bagby et al., "Essential versus complex autism: Definition of fundamental prognostic subtypes," *American Journal of Medical Genetics Part A*, vol. 135, no. 2, pp. 171–180, 2005.
- [61] A. M. Van Eeghen, M. B. Pulsifer, V. L. Merker et al., "Understanding relationships between autism, intelligence, and epilepsy: a cross-disorder approach," *Developmental Medicine and Child Neurology*, vol. 55, no. 2, pp. 146–153, 2013.
- [62] D. Cohen, N. Pichard, S. Tordjman et al., "Specific genetic disorders and autism: clinical contribution towards their

- identification,” *Journal of Autism and Developmental Disorders*, vol. 35, no. 1, pp. 103–116, 2005.
- [63] C. Amiet, I. Gourfinkel-An, A. Bouzamondo et al., “Epilepsy in autism is associated with mental retardation and gender: evidence from a meta-analysis,” *Biological Psychiatry*, vol. 64, no. 7, pp. 577–582, 2008.
- [64] C. Amiet, I. Gourfinkel-An, C. Laurent et al., “Epilepsy in multiplex autism pedigrees is associated with intellectual disability and known genetic and nongenetic causes, but not with gender,” *Molecular Autism*, vol. 4, no. 1, p. 47, 2013.
- [65] J. Xavier, C. Bursztejn, M. Stiskin, and D. Cohen, “Autism spectrum disorders: A developmental and dimensional approach toward a tailored therapeutic program,” *Research in Autism Spectrum Disorder*, vol. 18, pp. 21–33, 2015.
- [66] C. M. Benjamin, A. Colley, D. Donnai, H. Kingston, R. Harris, and L. Kerzin-Storarr, “Neurofibromatosis type 1 (NF1) knowledge, experience and reproductive decisions of affected patients and families,” *Journal of Medical Genetics*, vol. 30, no. 7, pp. 567–574, 1993.
- [67] K. North, J. M. Friedman, G. H. Gutmann, M. MacCollin, and V. Riccardi, “Cognitive function and academic performance,” in *In Neurofibromatosis: Phenotype, Natural History and Pathogenesis*, p. 380, John Hopkins University Press, Baltimore, 3rd edition, 1999.
- [68] M. Esposito, R. Marotta, M. Roccella et al., “Pediatric neurofibromatosis 1 and parental stress: a multicenter study,” *Neuropsychiatric Disease Treatment*, vol. 10, pp. 141–146, 2014.
- [69] W. Li, Y. Cui, S. A. Kushner et al., “The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1,” *Current Biology*, vol. 15, no. 21, pp. 1961–1967, 2005.
- [70] C. E. Bearden, G. S. Helleman, T. Rosser et al., “A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis 1,” *Annals of Clinical and Translational Neurology*, vol. 3, no. 4, pp. 266–279, 2016.
- [71] L. C. Krab, A. de Goede-Bolder, F. K. Aarsen et al., “Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial,” *The Journal of the American Medical Association*, vol. 300, no. 3, pp. 287–294, 2008.
- [72] T. van der Vaart, E. Plasschaert, A. B. Rietman et al., “Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial,” *Lancet Neurology*, vol. 12, no. 11, pp. 1076–1083, 2013.
- [73] M. Douniol, A. Jacquette, J. M. Guilé et al., “Psychiatric and cognitive phenotype in children and adolescents with myotonic dystrophy,” *European Child and Adolescent Psychiatry*, vol. 18, pp. 705–715, 2008.
- [74] P. J. De Vries and P. F. Bolton, “Genotype-phenotype correlations in tuberous sclerosis,” *Journal of Medical Genetics*, vol. 37, no. 5, e3 pages, 2000.